227 related articles for article (PubMed ID: 35753841)
1. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
Leav B; Straus W; White P; Leav A; Gaines T; Maggiacomo G; Kim D; Smith ER; Gurwith M; Chen RT;
Vaccine; 2022 Aug; 40(35):5275-5293. PubMed ID: 35753841
[TBL] [Abstract][Full Text] [Related]
2. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
Estephan L; Liu LT; Lien CE; Smith ER; Gurwith M; Chen RT;
Vaccine; 2023 Apr; 41(15):2615-2629. PubMed ID: 36925422
[TBL] [Abstract][Full Text] [Related]
3. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
Hernandez LM; Sumathy K; Sahastrabuddhe S; Excler JL; Kochhar S; Smith ER; Gurwith M; Chen RT;
Vaccine; 2022 Aug; 40(35):5263-5274. PubMed ID: 35715351
[TBL] [Abstract][Full Text] [Related]
4. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Folegatti PM; Jenkin D; Morris S; Gilbert S; Kim D; Robertson JS; Smith ER; Martin E; Gurwith M; Chen RT;
Vaccine; 2022 Aug; 40(35):5248-5262. PubMed ID: 35715352
[TBL] [Abstract][Full Text] [Related]
5. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults.
Fraiman J; Erviti J; Jones M; Greenland S; Whelan P; Kaplan RM; Doshi P
Vaccine; 2022 Sep; 40(40):5798-5805. PubMed ID: 36055877
[TBL] [Abstract][Full Text] [Related]
6. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Kochhar S; Excler JL; Kim D; Robertson JS; Fast PE; Condit RC; Drew S; Wood D; Gurwith M; Klug B; Whelan M; Khuri-Bulos N; Mallett Moore T; Smith ER; Chen RT;
Vaccine; 2020 Sep; 38(39):6184-6189. PubMed ID: 32747214
[TBL] [Abstract][Full Text] [Related]
7. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273.
Teo SP
J Pharm Pract; 2022 Dec; 35(6):947-951. PubMed ID: 33840294
[TBL] [Abstract][Full Text] [Related]
8. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
9. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
Kochhar S; Kim D; Excler JL; Condit RC; Robertson JS; Drew S; Whelan M; Wood D; Fast PE; Gurwith M; Klug B; Khuri-Bulos N; Smith ER; Chen RT;
Vaccine; 2020 Jul; 38(35):5734-5739. PubMed ID: 32653276
[TBL] [Abstract][Full Text] [Related]
10. Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population.
Butt AA; Talisa VB; Yan P; Shaikh OS; Omer SB; Mayr FB
Clin Infect Dis; 2022 Aug; 75(1):e579-e584. PubMed ID: 35245940
[TBL] [Abstract][Full Text] [Related]
11. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
Masuda T; Murakami K; Sugiura K; Sakui S; Philip Schuring R; Mori M
Vaccine; 2022 Mar; 40(13):2044-2052. PubMed ID: 35177302
[TBL] [Abstract][Full Text] [Related]
12. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
13. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
[TBL] [Abstract][Full Text] [Related]
14. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
Condit RC; Kim D; Robertson JS; Excler JL; Gurwith M; Monath TP; Pavlakis G; Fast PE; Smith J; Smith ER; Chen RT; Kochhar S;
Vaccine; 2020 Nov; 38(49):7708-7715. PubMed ID: 32907759
[TBL] [Abstract][Full Text] [Related]
15. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
16. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.
Kim D; Robertson JS; Excler JL; Condit RC; Fast PE; Gurwith M; Pavlakis G; Monath TP; Smith J; Wood D; Smith ER; Chen RT; Kochhar S;
Vaccine; 2020 Jul; 38(34):5556-5561. PubMed ID: 32571717
[TBL] [Abstract][Full Text] [Related]
17. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.
Eldridge JH; Egan MA; Matassov D; Hamm S; Hermida L; Chen T; Tremblay M; Sciotto-Brown S; Xu R; Dimitrov A; Smith ER; Gurwith M; Chen RT;
Vaccine; 2021 Sep; 39(38):5436-5441. PubMed ID: 34373117
[TBL] [Abstract][Full Text] [Related]
18. The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022.
Wallace M; Moulia D; Blain AE; Ricketts EK; Minhaj FS; Link-Gelles R; Curran KG; Hadler SC; Asif A; Godfrey M; Hall E; Fiore A; Meyer S; Su JR; Weintraub E; Oster ME; Shimabukuro TT; Campos-Outcalt D; Morgan RL; Bell BP; Brooks O; Talbot HK; Lee GM; Daley MF; Oliver SE
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(11):416-421. PubMed ID: 35298454
[TBL] [Abstract][Full Text] [Related]
19. Real-World Effectiveness of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in Preventing Confirmed Infection in Patients on Chronic Hemodialysis.
Butt AA; Talisa VB; Yan P; Shaikh OS; Omer SB; Mayr FB
Clin Infect Dis; 2022 Aug; 75(1):e617-e622. PubMed ID: 35139175
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
